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Background: Epidermal growth factor receptor (EGFR) mutation 
status in lung cancer can effectively predict EGFR-tyrosine kinase 
inhibitor (TKI) efficacy. We evaluated the role of dynamic plasma 
cell-free DNA EGFR mutation status in outcome prediction.
Methods: Advanced lung adenocarcinoma patients were enrolled 
and prospectively observed for outcomes of EGFR-TKI treatment. 
Peptide nucleic acid–zip nucleic acid polymerase chain reaction 
clamp method was developed to assess EGFR mutations in matched 
tumor and serial plasma cell-free DNA specimens.
Results: A total of 72 patients were enrolled in this study, of which 
62 patients (86.1%) had EGFR-mutant tumors (34 patients with exon 
19 deletions, and 28 patients with L858R). Pretreatment plasma 
used for EGFR mutation testing showed a sensitivity of 59.7% and a 
specificity of 100%. Detection sensitivity was significantly higher in 
stage IV-M1b patients compared with stage IIIb and IV-M1a patients 
(78.0% versus 23.8%, p < 0.001). All patients who presented with 
EGFR-mutant tumors received first-line EGFR-TKI therapy. The 
objective response rate and disease control rate were 74.2% and 
82.3%, respectively. Median progression-free survival and overall 
survival were 8.8 months (95% CI: 6.6–11.0) and 20.5 months (95% 
CI 15.1–26.0), respectively. Failure to clear plasma EGFR muta-
tions after EGFR-TKI treatment was an independent predictor of 
lower disease control rate (odds ratio 5.26 [95% CI: 1.13–24.44]; 
p = 0.034), shorter progression-free survival (hazard ratio: 1.97 [95% 
CI: 1.33–2.91]; p = 0.001), and shorter overall survival (hazard ratio: 
1.82 [95% CI: 1.04–3.18], p = 0.036).
Conclusion: Changes in plasma EGFR mutation status can be suc-
cessfully assessed using the peptide nucleic acid–zip nucleic acid 
polymerase chain reaction clamp method and can serve as an inde-
pendent outcome predictor.
Key Words: Peptide nucleic acid–zip nucleic acid polymerase chain 
reaction clamp, plasma cell-free DNA, Epidermal growth factor 
receptor mutations, Lung adenocarcinoma.
(J Thorac Oncol. 2015;10: 603–610)
Activating mutations of epidermal growth factor recep-tor (EGFR) gene are the most common genetic altera-
tions in lung adenocarcinoma in Eastern Asians,1 and serve 
as an important predictor of EGFR-tyrosine kinase inhibitor 
(TKI) efficacy. Compared with chemotherapy, EGFR-TKI has 
demonstrated a significantly higher response rate, longer pro-
gression-free survival (PFS), and better quality of life in non–
small-cell lung cancer (NSCLC) patients harboring activating 
EGFR mutations.2,3 These encouraging results led clinicians 
to use EGFR-TKI as the first-line therapy for EGFR-mutant 
NSCLC patients.4,5
A recently published molecular testing guideline for 
EGFR mutations suggested that EGFR molecular testing 
should be mandatory in advanced stage disease as an aid to 
selecting suitable patients for EGFR-TKI treatment.6 However, 
adequate specimens are not always available because tissue 
sampling in lung cancer is associated with potential complica-
tions,7 and small specimens usually carry a higher molecu-
lar testing failure rate.8 It has also been shown that plasma 
specimens obtained from lung cancer patients contain a 
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higher cell-free DNA (cfDNA) level than those from cancer-
free patients,9 which may be because of the release of tumor 
DNA into the blood via tumor cell necrosis or apoptosis.10 
Therefore, plasma cfDNA is considered a potential alternative 
specimen for EGFR mutation testing.
Zip nucleic acids (ZNA), which are oligonucleotides 
conjugated with cationic spermine units that can increase the 
affinity for their target by decreasing the electrostatic repul-
sions, have been reported to be potent probes or primers for 
polymerase chain reaction (PCR) assay.11,12 Although several 
previous studies successfully detected EGFR mutations in 
plasma cfDNA, their reported accuracy rates varied widely,13 
and few large cohort studies have investigated the dynamic 
changes of EGFR mutation status in plasma. In this study, we 
developed the peptide nucleic acid–ZNA PCR (PNA–ZNA 
PCR) clamp method to dynamically monitor the plasma EGFR 
mutation status in patients with advanced EGFR-mutant lung 
adenocarcinoma before and after the initiation of EGFR-TKI 
treatment as well as to evaluate its role in outcome prediction.
METHODS
Patients
This was a single-center prospective observational 
study. To be eligible for the study, patients were required to 
have pathologically confirmed lung adenocarcinoma, treat-
ment-naïve and inoperable stage IIIb or IV diseases according 
to the 7th edition of the American Joint Committee for Cancer 
staging system,14 available tumor and serial plasma specimens 
for EGFR mutation testing, and clinically measurable disease. 
Patients were excluded if they had only evaluable disease, 
other active malignancy, and any prior history of treatment 
that could influence the tumor burden, such as an operation 
or administration of systemic antitumor medications. Ten 
patients with EGFR-wild-type (wt) tumors were recruited for 
this study to evaluate the specificity of plasma EGFR muta-
tion status analysis. All other enrollees had to harbor com-
mon EGFR mutations (either exon 19 deletions or exon 21 
L858R) in their tumor specimens. This study was approved by 
the Institutional Review Board of Taichung Veterans General 
Hospital. Written informed consents for genetic testing and 
clinical records were obtained from all patients.
EGFR-TKI Treatment and Outcome Evaluation
All enrolled patients who presented with detectable 
EGFR mutations in their tumor specimens received EGFR-
TKI as the first-line treatment with either gefitinib or erlotinib. 
However, the first dose of EGFR-TKI was not prescribed until 
after baseline plasma specimens were collected. These patients 
were then prospectively surveyed for tumor responses and sur-
vival outcomes. In the case of patients with EGFR-wt tumors, 
the main treatment was chemotherapy, which was determined 
by each attending physician; hence, the treatment outcomes of 
these patients were not assessed in this study.
Chest computed tomographies and other imaging stud-
ies required for response evaluation were performed every 
8–12 weeks. Unidimensional measurement as defined by the 
Response Evaluation Criteria in Solid Tumors (Version 1.1) 
was used in this study.15 The objective response rate (ORR), 
disease control rate (DCR), PFS, and overall survival (OS) of 
EGFR-TKI treatment were assessed.
Specimens Collection and EGFR Mutation Tests
For patients harboring EGFR mutations in tumor speci-
mens, we collected plasma at baseline, 10 weeks after EGFR-
TKI treatment, and at the time of disease progression. For 
patients with EGFR-wt tumors, only baseline plasma speci-
mens were collected. Tumor tissue DNA was extracted using 
the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) 
and plasma cfDNA was purified from 1 ml of ethylenediami-
netetraacetic acid plasma using the same kit. The elution vol-
umes of the DNeasy Mini Spin Column for tumor and plasma 
DNA extraction were 200 μl and 80 μl, respectively.
EGFR mutation status in matched tumor and plasma 
specimens was assessed using PNA–ZNA PCR clamp 
method, which was modified from PNA-locked nucleic acid 
PCR clamp method developed by Nagai et al.,16 in which 
ZNA probes was substituted for locked nucleic acid probes to 
provide higher affinity for their targets and greater detection 
sensitivity (the detection sensitivity for both exon 19 dele-
tions and exon 21 L858R detection could be up to 1:1000; 
Supplementary Figure 1, SDC 1, http://links.lww.com/JTO/
A759). PNA oligos were synthesized by PanaGene (Daejeon, 
Korea) and ZNA probes, oligonucleotides conjugated with 
four cationic spermine units at the 3′ end, were provided by 
Metabion (Steinkirchen, Germany). PNA–ZNA PCR clamp 
was performed in a 25 μl mixture, containing 0.5 units of 
Blend Taq DNA Polymerase (Toyobo Bio, Osaka, Japan), 1× 
Blend Taq Buffer, 400 μM of dNTP, 200 nM of forward and 
reverse PCR primers, 200 nM ZNA probes, 5 μM PNA clamp 
probes, and 5 μl of eluted DNA. The PCRs were performed 
using Rotorgene 6000 (Qiagen, Hilden, Germany) with the 
following cycling conditions: hold at 94°C for 3 minutes; 
complete 50 cycles of denaturation at 94°C for 20 seconds; 
anneal at 60°C for 30 seconds followed by extension at 72°C 
for 20 seconds.
Statistical Methods
Univariate analyses of ORR, DCR, and detection sensi-
tivity were performed using Fisher’s exact test. The Kaplan–
Meier method was used to estimate PFS and OS. Differences 
in survival time were analyzed by log-rank test. Logistic 
regression model and Cox proportional hazard model were 
used to evaluate the impact of plasma EGFR mutation status 
on the outcome of EGFR-TKI treatment and for multivariate 
analyses of responses and survival outcomes. In the stepwise 
procedure, the significant level for entry and removal were 
0.05 and 0.10, respectively. All statistical tests were carried 
out using SPSS 15.0 (SPSS Inc., Chicago, IL). Two-tailed 
tests and p values <0.05 for significance were used.
RESULTS
Patient Characteristics
A total of 72 lung adenocarcinoma patients met the 
enrollment criteria and participated in the study from May 
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2012 to October 2013. This study was conducted at Taichung 
Veterans General Hospital. The baseline characteristics of 
patients are shown in Supplementary Table 1 (SDC 2, http://
links.lww.com/JTO/A760). In summary, the median age was 
64.5 years, 40 patients (55.6%) were female, 49 patients 
(68.1%) were nonsmokers, 55 patients (76.4%) had Eastern 
Cooperative Oncology Group performance status (ECOG PS) 
0–1, and 68 patients (94.4%) presented with stage IV disease 
(20 patients with M1a and 48 patients with M1b metastases).
Correlation of EGFR Mutation Status 
with Paired Tumor and Baseline 
Plasma cfDNA Specimens
The EGFR mutation status in tumors was initially ana-
lyzed by PNA–ZNA PCR clamp method and the results were 
summarized in Supplementary Table 1 (SDC 2, http://links.
lww.com/JTO/A760). Ten EGFR-wt patients (13.9%) were 
recruited for the purpose of evaluating the specificity of plasma 
EGFR mutation status. The remaining 62 patients (86.1%) had 
detectable EGFR mutations in their tumor specimens, includ-
ing 34 patients with exon 19 deletions and 28 patients with 
exon 21 L858R. Tumor mutation status was verified using 
matrix-assisted-laser-desorption–ionization time-of-flight 
mass spectrometry, which is established as a standard EGFR 
detection method in Taiwan by National Taiwan University 
Center of Genomic Medicine (an ISO15189-certified medical 
laboratory); no discrepancies were noted between the muta-
tion types assessed by either detection method in all patients. 
Supplementary Figure 2 (SDC 3, http://links.lww.com/JTO/
A761) shows the results of PNA–ZNA PCR clamp reactions 
in plasma EGFR mutation detection; both exon 19 deletions 
and L858R were successfully detected.
The results of the correlation of EGFR mutation status 
with tumor and baseline plasma cfDNA specimens are shown 
in Table 1. Of the 62 patients with EGFR-mutant tumors, 37 
patients had detectable EGFR mutations in baseline plasma 
specimens, yielding a sensitivity of 59.7%; all mutation types 
of these patients were consistent between the plasma and 
tumor specimens. Of 10 patients with EGFR-wt tumors, the 
plasma cfDNA specimens were all negative for EGFR muta-
tions. Therefore, the detection specificities for each tumor 
genotype were 100%.
As shown in Table 2, the only factor that correlated 
significantly with the detection sensitivity was tumor stage. 
Patients with stage IV-M1b diseases carried a significantly 
higher EGFR mutation detection sensitivity in baseline plasma 
than those with stage IIIb and stage IV-M1a diseases (78.0% 
versus 23.8%, p < 0.001). There was no significant correlation 
between EGFR mutation types and the detection sensitivity.
Efficacy of EGFR-TKI Treatment in 
Patients with EGFR-Mutant Tumors
All 62 patients with EGFR-mutant tumors received 
EGFR-TKI as the first-line treatment (58 with gefitinib and 
4 with erlotinib). Forty-six patients achieved partial response 
and five patients had stable disease. No patient achieved com-
plete response. The ORR and DCR were 74.2% and 82.3%, 
respectively. Results of univariate analysis of ORR and 
DCR are shown in Table 3. Patients with exon 19 deletions 
were associated with a higher ORR than those with L858R 
(85.3% versus 60.7%, p = 0.041). No other factors were sig-
nificantly correlated with ORR and DCR. The median PFS 
was 8.8 months (95% CI: 6.4–11.2) and the median OS was 
20.5 months (95% CI: 15.1–26.0). In the univariate analysis, 
patients of a relatively younger age (less than 65 years) and 
better ECOG PS (0–1) were associated with a longer OS (p = 
0.016 and 0.002, respectively). No other factors were signifi-
cantly correlated with PFS and OS (data not shown).
Correlation between Plasma EGFR Mutation 
Status and EGFR-TKI Treatment Outcomes
Of the 62 patients with EGFR-mutant tumors, 37 
patients (59.7%) had detectable EGFR mutations in baseline 
plasma cfDNA specimens. There was no significant difference 
in either ORR or DCR between patients with positive and neg-
ative baseline plasma EGFR mutations (75.7% versus 72.0%, 
p = 0.774, and 81.1% versus 84.0%, p = 1.000, respectively). 
Similar results were observed in PFS (8.7 months [95% CI: 
8.1–9.2] versus 10.6 months [95% CI: 5.3–15.9], p = 0.365) 
and OS (20.5 months [95% CI: 15.6–25.5] versus not reached, 
p = 0.715) analyses (Supplementary Figure 3, SDC 4, http://
links.lww.com/JTO/A762).
In addition, we evaluated the role of the dynamic 
changes of plasma EGFR mutation status in outcome pre-
diction. We delineated three groups of patients according to 
their plasma EGFR mutation status. All 25 patients without 
detectable plasma EGFR mutations at baseline remained 
negative for plasma EGFR mutations after EGFR-TKI treat-
ment and were classified as Group A. Of 37 patients with 
initially detectable EGFR mutations in plasma, 28 patients 
(75.7%) had clearance of baseline plasma EGFR mutations 
after treatment and were classified as Group B. The remaining 
TABLE 1.  Sensitivities for Detecting Tumor EGFR Mutation Status Using Matched Plasma cfDNA Samples
Tumor Genotype
Stage III/IV-M1a
% (n/N)
Stage IV-M1b
%, (n/N)
Total
% (n/N)
EGFR-mutanta 23.8 (5/21) 78.0 (32/41) 59.7 (37/62)
  Exon 19 deletions 25.0 (3/12) 81.8 (18/22) 61.8 (21/34)
  Exon 21 L858R 22.2 (2/9) 73.7 (14/19) 57.1 (16/28)
EGFR-wild type 0.0 (0/3) 0.0 (0/7) 0.0 (0/10)
ap < 0.001 for stage III/IV-M1a versus stage IV-M1b by Fisher’s exact test.
EGFR, epidermal growth factor receptor; cfDNA, cell-free DNA; n/N, patients with compatible EGFR mutation status in matched plasma and tumor samples/patients been assessed.
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nine patients (24.3%), who stayed positive for EGFR muta-
tions in plasma and whose mutation types were consistent 
with corresponding baseline plasma and tumor results, were 
classified as Group C. The results of outcome analyses are 
shown in Table 4 and Figure 1. The ORRs of Group A, B, and 
C patients were 72.0%, 85.7%, and 44.4%, respectively; the 
DCRs were 84.0%, 89.3%, and 55.6%, respectively. Group C 
patients with persistently detectable plasma EGFR mutations 
were associated with a significantly lower ORR and DCR 
than Group A and B patients (p = 0.042 and 0.044, respec-
tively). The PFSs of Group A, B, and C patients were 10.6 
months (95% CI: 5.3–15.9), 10.9 months (95% CI: 7.5–14.2), 
and 4.8 months (95% CI: 0.0–12.8), respectively; OSs were 
not reached (OS probability was 0.62 at 22.2 months), 20.5 
months (95% CI not applicable), and 10.8 months (95% CI: 
4.9–16.8), respectively. Group C patients with persistently 
TABLE 2.  Univariate Analysis of Baseline Plasma cfDNA EGFR Mutation Status in Tumor EGFR-Mutant Patients
Factor Characteristics Sensitivity, % (n/Na) P Valueb
Age <65 years 57.6 (19/33) 0.798
≥65 years 62.1 (18/29)
Gender Male 61.5 (16/26) 1.000
Female 58.3 (21/36)
Smoking status Nonsmokers 61.4 (27/44) 0.778
Current/ex-smokers 55.6 (10/18)
ECOG PS 0–1 56.3 (27/48) 0.367
≥2 71.4 (10/14)
Mutation types Exon 19 deletions 61.8 (21/34) 0.797
Exon 21 L858R 57.1 (16/28)
Stage IIIb & IV-M1a 23.8 (5/21) <0.001
IV-M1b 78.0 (32/41)
an/N = plasma cfDNA/tumor with EGFR mutations.
bBy Fisher’s exact test.
cfDNA, cell-free DNA; EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group performance status.
TABLE 3.  Univariate Analysis of Objective Response Rate and Disease Control Rate in Patients Harboring EGFR Mutations (n = 62)
Patient No. ORR (%) P Valuea DCR (%) P Valuea
Age (years)
  <65 33 72.7 1.000 81.8 1.000
  ≥65 29 75.9 82.8
Gender
  Male 26 65.4 0.242 76.9 0.502
  Female 36 80.6 86.1
Smoking
  Nonsmokers 44 79.5 0.200 84.1 0.715
  Current/ex-smokers 18 61.1 77.8
ECOG PS
  0–1 48 72.9 1.000 81.3 1.000
  ≥2 14 78.6 85.7
Stage
  IIIb & IV-M1a 21 81.0 0.542 90.5 0.305
  IV-M1b 41 70.7 78.0
Mutation types
  Exon 19 deletions 34 85.3 0.041 88.2 0.200
  Exon 21 L858R 28 60.7 75.0
EGFR-TKI
  Gefitinib 58 74.1 1.000 81.0 1.000
  Erlotinib 4 75.0 100.0
aBy Fisher’s exact test.
ORR, objective response rate; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, 
tyrosine kinase inhibitors.
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detectable plasma EGFR mutations were associated with a 
significantly shorter PFS and OS than Group A and B patients 
(p < 0.001 and p= 0.002, respectively). Because a signifi-
cant portion of patients (30.6%) were still receiving EGFR-
TKI treatment, the EGFR mutation status in postprogression 
plasma was not mature enough to be analyzed.
As shown in Figure 2, two patients who had detectable 
exon 19 deletions in baseline plasma received gefitinib as the 
first-line treatment. Although both of them initially had favor-
able responses, as shown by chest computed tomography, the 
patient whose post-EGFR-TKI plasma remained positive for 
EGFR mutations did have a shorter PFS. Of nine patients with 
persistently detectable plasma EGFR mutations, four patients 
achieved partial response, one patient had stable disease, and 
four patients had progressive disease at the first post-EGFR-
TKI chest computed tomography follow-up. Therefore, 
post-EGFR-TKI plasma EGFR mutation status not only iden-
tified patients with primary resistance to EGFR-TKI but also 
patients who responded well initially but soon experienced 
disease progression.
Because exon 19 deletions were predictor of better 
response, we further examined whether it would be easier to 
clear exon 19 deletions from plasma after EGFR-TKI treatment. 
In 37 patients with initially detectable plasma EGFR muta-
tions, there was no significant difference in the clearance rate 
of EGFR mutations between these two mutations (p = 0.136).
TABLE 4.  Impact of Plasma cfDNA EGFR Mutation Status on the Outcome of EGFR-TKI Treatment (n = 62)
Best Responses Percentage (%) Odds Ratio 95% CI P1 P2
Objective response rate
  Group A vs. B 72.0 vs. 85.7 0.43 0.11–1.69 0.226 0.042
  Group A vs. C 72.0 vs. 44.4 3.21 0.66–15.58 0.147
  Group B vs. C 85.7 vs. 44.4 7.50 1.39–40.56 0.019
Disease control rate
  Group A vs. B 84.0 vs. 89.3 0.63 0.13–3.14 0.573 0.044
  Group A vs. C 84.0 vs. 55.6 4.20 0.77–22.87 0.097
  Group B vs. C 89.3 vs. 55.6 6.67 1.13–39.47 0.037
Survival Time Time (Months) Hazard Ratio 95% CI P1 P2
Progression-free survival
  Group A vs. B 10.6 vs. 10.9 0.97 0.49–1.91 0.933 <0.001
  Group A vs. C 10.6 vs. 4.8 1.85 1.18–2.90 0.007
  Group B vs. C 10.9 vs. 4.8 4.42 1.85–10.57 0.001
Overall survival
  Group A vs. B NR vs. 20.5 1.35 0.43–4.31 0.608 0.002
  Group A vs. C NR vs. 10.8 2.06 1.09–3.88 0.025
  Group B vs. C 20.5 vs. 10.8 5.47 1.45–20.62 0.012
Group A: no detectable EGFR mutations in baseline plasma (n = 25). Group B: detectable EGFR mutations in baseline plasma and then clearance of plasma EGFR mutations after 
EGFR-TKI treatment (n = 28). Group C: persistence of detectable EGFR mutations in plasma (n = 9). P1: individual comparison between three groups by logistically regression model 
and Cox proportional hazard model for best responses and survival time, respectively. P2: comparison of group A and B vs. group C by Fisher’s exact test and log-rank test for best 
response and survival time, respectively.
cfDNA, plasma cell-free DNA; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors; NR, not reached.
FIGURE 1.  Kaplan–Meier plot 
showing progression-free survival 
(A) and overall survival (B) according 
to changes in plasma cfDNA EGFR 
mutation status (group A: no detect-
able EGFR mutations in baseline 
plasma [n = 25]; group B: detectable 
EGFR mutations in baseline plasma 
followed by clearance of plasma EGFR 
mutations after EGFR-TKI treatment 
[n = 28]; group C: persistent detect-
able EGFR mutations in plasma  
[n = 9]). EGFR, epidermal growth 
factor receptor; TKI, tyrosine kinase 
inhibitor; cfDNA, cell-free DNA.
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Failure to Clear Plasma EGFR Mutations 
after EGFR-TKI Treatment Predicts an 
Independently Poor Outcome
Results of multivariate analysis are shown in 
Supplementary Table 2 (SDC 2, http://links.lww.com/JTO/
A760). In the multivariate logistic regression model for ORR 
analysis, no covariate reached a significant level in the model 
but we observed a trend toward a higher ORR in Group A 
and B than in Group C patients (odds ratio 3.94 [95% CI: 
0.85–18.23]; p = 0.079). In the case of DCR analysis, dynamic 
change of plasma EGFR mutation status was the only factor 
independently associated with DCR (odds ratio 5.26 [95% CI: 
1.13–24.44], p = 0.034) and Group C patients were less likely 
to experience disease control. Similarly, in the multivariate 
Cox proportional hazard model, Group C patients were found 
to be independently associated with a shorter PFS (hazard 
ratio [HR]: 1.97 [95% CI: 1.33–2.91]; p = 0.001) and OS (HR: 
1.82 [95% CI: 1.04–3.18]; p = 0.036). Patients with ECOG 
PS 0–1 were more likely to experience a longer OS (HR: 1.84 
[95% CI: 1.09–3.11], p = 0.022).
DISCUSSION
Tumor EGFR mutation status is the key predictor of 
EGFR-TKI efficacy in lung cancer. Because adequate tumor 
specimens are not always available, many previous studies 
evaluated the potential use of blood as an alternative specimen 
for EGFR mutation testing.13,17 However, the baseline char-
acteristics of these studies varied widely and the results were 
often inconsistent. By contrast, our study cohort was relatively 
homogeneous because all patients had advanced treatment-
naïve lung adenocarcinoma and were enrolled and observed 
prospectively. Although serum has been used in several stud-
ies,18–20 plasma was recently been reported to be a better source 
of cfDNA for the detection of EGFR mutations.21 Our results 
showed that EGFR mutations could be successfully detected 
in plasma specimens using the PNA–ZNA PCR clamp method 
and that dynamic plasma EGFR mutation status can effec-
tively predict the outcome of EGFR-TKI treatment.
Many studies have reported successful detection of 
EGFR mutations in plasma, but only a few have empha-
sized the predictive value of dynamic EGFR mutation status 
in plasma.22–24 More prospective studies with larger cohorts 
are still needed. In this study, we showed that failure to clear 
plasma EGFR mutations after EGFR-TKI treatment was an 
independent predictor of poor disease control and reduced 
survival time. Moreover, post-EGFR-TKI plasma EGFR 
mutation status could not only be used to identify patients 
with primary resistance to EGFR-TKI but also patients who 
responded well initially but soon experienced disease progres-
sion. Further studies are warranted to establish optimal treat-
ment for such patients.
The main reasons for inconsistent results in previ-
ous studies could be traced to the use of different detection 
methods.13 In addition, both tumor stage and proportion of 
EGFR-wt patients might account for the divergent results of 
previous studies. In this study, we disclose that EGFR muta-
tions were more frequently detected in plasma obtained from 
patients with stage IV-M1b diseases than from those with 
stage IIIb or stage IV-M1a diseases, which suggests a correla-
tion between tumor burden and detection sensitivity. Patients 
with more advanced diseases were more likely to have detect-
able plasma EGFR mutations. These results are similar to the 
observations of previous studies.25–27 In contrast with previ-
ous studies, this study assessed the tumor stage using the 7th 
edition of the American Joint Committee for Cancer staging 
system,14 which may lead to different patient sorting, such 
as those with malignant pleural effusion. Furthermore, it 
could be surmised that studies enrolling a higher number of 
EGFR-wt patients would show a higher consistency between 
tumor and blood specimens.28,29
Recently, Oxnard et al.30 demonstrated that plasma 
cfDNA genotyping by droplet digital PCR could be used to 
detect and monitor EGFR sensitizing and drug resistance 
mutations in NSCLC patients. However, the number of cases 
was small and the authors did not perform survival time 
analysis. In this study, we classified patients into three groups 
according to the dynamic changes in their plasma EGFR 
mutation status and identified patients with poor outcomes 
earlier in the course of treatment. The method can provide a 
chance to adjust the treatments for patients with potentially 
poorer outcome.
In univariate analysis, patients harboring with exon 19 
deletions were associated with a higher ORR than those with 
L858R, which is consistent with the observations of previous 
studies.31,32 However, there was no significant difference in the 
clearance rate of EGFR mutations between these two muta-
tions. Furthermore, in multivariate analysis, neither responses 
nor survival time were significantly associated with mutation 
types. The dynamic status of plasma EGFR mutations was the 
only factor that predicted DCR and both PFS and OS indepen-
dently. Similar to the finding of previous studies,33,34 ECOG 
PS also served as an independent predictor of OS.
There are three major limitations of this study. First, we 
only assessed exon 19 deletions and L858R. However, our 
FIGURE 2.  Case presentation demonstrated predictive 
value of post-EGFR-TKI cfDNA EGFR mutation status. PR, 
partial response; 19Del, exon 19 deletions; Neg, negative; 
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase 
 inhibitor; cfDNA, cell-free DNA.
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results could be applied to most EGFR-mutant patients because 
these two mutation types account for more than 90% of total 
EGFR mutations.1 Future investigations are warranted to 
expand the detection spectrum, including the T790M resistance 
mutation. Second, the EGFR mutation status in postprogres-
sion plasma was not mature enough to be analyzed. Herein, we 
emphasized the value of identifying patients with a relatively 
poor prognosis early in the course of treatment; this strategy 
allows us to potentially make adjustments to their treatment. 
Third, compared with digital PCR and next-generation technol-
ogies, our detection method is not superior in terms of detection 
sensitivity, and it lacks absolute quantification. However, real-
time PCR-based methods should be easier to apply in clinical 
practice because of their availability and lower costs.35
In conclusion, we demonstrated that EGFR mutations 
can be successfully detected in plasma cfDNA using the PNA–
ZNA PCR clamp method and showed that the detection sen-
sitivity was higher in patients with more advanced diseases. 
Furthermore, our study demonstrated that dynamic changes 
in plasma EGFR mutation status can serve as an independent 
predictor of patients’ outcome and be used to help identify 
patients at risk of rapid disease progression. Further stud-
ies are warranted to determine how to adjust the treatments 
according to dynamic status of plasma EGFR mutations.
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